Delving into the Latest Updates on AO-1535 with Synapse

Overview

Basic Info

Drug Type

Unknown

Synonyms

Target-

Mechanism-

Therapeutic Areas

Skin and Musculoskeletal DiseasesOther Diseases

Active Indication-

Inactive Indication

InflammationSkin Diseases

Originator Organization

Fidia Farmaceutici SpA

Active Organization-

Inactive Organization

Fidia Farmaceutici SpA

Drug Highest PhaseDiscontinuedPreclinical

First Approval Date-

Regulation-

AO 1535 is a semisynthetic monoglycosylceramide derived from O-glycosilated sphingosine, with a chemical structure similar to the glycolipids present in many mammalian tissues. In the epidermis monoglycosylceramides contribute to consolidate the structure of cutaneous layers. It has been recently shown that sphingosine and its derivatives are potent inhibitors of Protein kinase C, and block the 'respiratory burst' of phagocitic cells. In macrophages, like in neutrophils, the reactive oxygen intermediates are produced by a membrane associated enzymatic complex, NADPH-oxidase, which is activated by Protein kinase C. This study demonstrates that AO 1535 is able to inhibit the production of reactive oxygen intermediates in human monocytes and macrophages stimulated by phorbol ester and chemotactic tetrapeptide, suggesting a potential clinical application of AO 1535 in the treatment of inflammatory dermatoses.

100 Deals associated with AO-1535

Login to view more data